Shingles (Zoster) Vaccines
Live-attenuated and recombinant adjuvanted vaccines for herpes zoster prevention
This page catalogs 2 shingles vaccine products. The transition from the live-attenuated Zostavax to the recombinant adjuvanted Shingrix represents a shift toward higher-efficacy non-live platforms. Shingrix, which uses the AS01B adjuvant system, demonstrated substantially higher and more durable efficacy than its predecessor and is the current standard for adults aged 50 and older.
Last updated: April 2026.
Shingles (Zoster) Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Zostavax | Zoster vaccine, live (Oka/Merck) | Merck | Live-attenuated (VZV) | FDA Licensed, 2006; Discontinued 2020 | Replaced by Shingrix |
| Shingrix | Zoster vaccine recombinant, adjuvanted | GSK | Recombinant + AS01B adjuvant | FDA Licensed, 2017 | Current standard; 2-dose series for adults 50 and older |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026). Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.